Sign in
Explore the registryTrack Osimertinib 80 mg/40 mg's trials

TARGET

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Osimertinib 80 mg/40 mgOngoingActive not recruitingPhase 2Open NCT05526755 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…